NASDAQ: DFTX
Definium Therapeutics, Inc.
$44.27
▼ -2.77 (-5.88%)as of 2026-07-01
1-year price · 252 sessions
Key stats
52-week range$44.27
$6.68$47.04
Today
- Open
- 46.83
- Day high
- 47.20
- Day low
- 44.08
- Prev close
- 47.04
- Volume
- 1.4M
Valuation
- Mkt cap
- $4.8B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 17.3
- P/S
- —
Dividend
- Yield
- —
- Per share
- —
Insider & institutional activity · SEC Form 4 / 13F
- ▼Insiders net selling -$2.6M over the last 3 months (0 open-market buys, 5 sales)
- 🏛Institutions accumulating (13F)
Definium Therapeutics, Inc. (DFTX) is a Healthcare company listed on NASDAQ. The stock is up 604% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 5 sales (SEC Form 4).
Definium Therapeutics, Inc. (DFTX) financials & analyst ratings
Fundamentals (TTM)
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
Growth & returns
Revenue growth—
Revenue growth (fwd)—
EPS growth—
Return on equity-85.2%
Return on assets-59.2%
Analyst consensus · 8 analysts
BuyBuy 8Hold 0Sell 0Avg target $54 (+21.1%)Range $30–$74
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
DFTX earnings date, history & EPS estimates
Next earnings
Jul 30, 2026in NaN days
EPS est $-0.55 · Revenue est —
Track record
Beat EPS in 5 of 12 quarters
Avg surprise -30.8% (last 4 quarters)
Earnings history
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.49 | $-0.71 | -44.3% | — | — |
| Nov 6, 2025 | $-0.52 | $-0.78 | -50.0% | — | — |
| Jul 31, 2025 | $-0.38 | $-0.50 | -31.6% | — | — |
| May 8, 2025 | $-0.36 | $-0.35 | +2.8% | — | — |
| Mar 6, 2025 | $-0.33 | $-0.41 | -24.2% | — | — |
| Nov 7, 2024 | $-0.29 | $-0.27 | +6.9% | — | — |
| Feb 28, 2024 | $-0.48 | $-0.59 | -22.9% | $5M | — |
| Nov 2, 2023 | $-0.65 | $-0.53 | +18.5% | — | — |
| Aug 3, 2023 | $-0.54 | $-0.72 | -33.3% | — | — |
| May 4, 2023 | $-0.41 | $-0.51 | -24.4% | — | — |
| Mar 9, 2023 | $-0.49 | $-0.27 | +44.9% | — | — |
| Nov 10, 2022 | $-0.58 | $-0.56 | +3.4% | — | — |
DFTX insider trading activity (SEC Form 4)
Sentiment
0/100
Buys (3m)
0
Sells (3m)
5
Net (3m)
-$2.6M
Insider trades by month Buys Sells
Mar
Jun
Context3-month price +148.9%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 26, 2026 | Barrow Robertdirector, officer: Chief Executive Officer | Sell | 29,208 | $45.03 |
| Jun 26, 2026 | Karlin Danielofficer: Chief Medical Officer | Sell | 10,035 | $45.03 |
| Jun 26, 2026 | Wiley Matthew T.officer: Chief Commercial Officer | Sell | 2,867 | $45.03 |
| Jun 26, 2026 | Sullivan Markofficer: Chief Legal Officer | Sell | 13,008 | $45.03 |
| Jun 26, 2026 | Roberts Brandiofficer: Chief Financial Officer | Sell | 3,013 | $45.03 |
| Jun 22, 2026 | Roberts Brandiofficer: Chief Financial Officer | Grant | 62,500 | — |
| Jun 22, 2026 | Sullivan Markofficer: Chief Legal Officer | Grant | 62,500 | — |
| Jun 22, 2026 | Karlin Danielofficer: Chief Medical Officer | Grant | 100,000 | — |
| Jun 22, 2026 | Wiley Matthew T.officer: Chief Commercial Officer | Grant | 62,500 | — |
| Jun 22, 2026 | Barrow Robertdirector, officer: Chief Executive Officer | Grant | 375,000 | — |
| Jun 15, 2026 | Bruhn Suzanne Louisedirector | Grant | 4,666 | — |
| Jun 15, 2026 | Bruhn Suzanne Louisedirector | Grant | 19,188 | $24.11 |
| Jun 15, 2026 | Adsett Rogerdirector | Grant | 14,620 | $24.11 |
| Jun 15, 2026 | CRYSTAL ROGERdirector | Grant | 4,666 | — |
| Jun 15, 2026 | CRYSTAL ROGERdirector | Grant | 19,188 | $24.11 |
Source: DFTX SEC Form 4 filings, latest Jun 26, 2026. For informational purposes only — not investment advice.
See the full DFTX insider & 13F page →Track DFTX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free